Gilead Sciences Singapore Discusses Access and Affordability of CAR T-Cell Therapy in Singapore and Beyond

19 June 2023 | Monday | News

In an exclusive interview with BioPharma APAC, Margaret Yoong, Associate Director of Medical Affairs & Country Medical Lead at Gilead Sciences Singapore, sheds light on the critical topic of CAR T-cell therapy access and affordability. With a focus on Singapore and its potential impact in the Asia-Pacific region, Yoong provides valuable insights into the current landscape, key considerations, and strategies to enhance accessibility to innovative cancer treatments.
Margaret Yoong, Associate Director of Medical Affairs & Country Medical Lead at Gilead Sciences Singapore,

Margaret Yoong, Associate Director of Medical Affairs & Country Medical Lead at Gilead Sciences Singapore,

Can you elaborate on the current availability and accessibility of CAR T-cell therapies in Singapore? What are the key considerations or barriers that need to be addressed to improve access for patients?

In 2021, Singapore became the first country in Southeast Asia to approve CAR T-cell therapy for medical use. At the time of writing, there are two cell therapies that have received approval from the Health Sciences Authority (HSA) in Singapore.1 These therapies are only approved to treat a limited set of haematological malignancies, including non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukaemia (ALL).


In March 2023, the HSA of Singapore granted marketing authorisation for Yescarta® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory large B- cell lymphoma (LBCL), after two or more lines of systemic therapy, including diffuse large B- cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma and high grade B-cell lymphoma, DLBCL arising from follicular lymphoma.1


Axicabtagene ciloleucel must be administered at a certified healthcare facility. Currently, institutions such as the Singapore General Hospital (SGH) and Parkway Cancer Centre are qualified to administer CAR-T cell therapy to patients. Patient safety is a priority and Gilead and Kite Oncology use a rigorous training process in accordance with the requirements of our approved Risk Management Plan to qualify these certified healthcare facilities that can administer axicabtagene ciloleucel.


In terms of financing innovative therapies like CAR T-cell therapy, what strategies or models can be implemented to ensure affordability for patients while maintaining the sustainability of the healthcare system in Singapore?

When developing the price of CAR T-cell therapy, Gilead and Kite Oncology follow an industry benchmarked approach that is grounded in the belief that pricing should be driven by the value that a therapy provides to patients and their carers, clinicians, payors and the broader healthcare system. Gilead and Kite Oncology continue to work closely with stakeholders in Singapore to enable timely and sustainable access to CAR T-cell therapy for eligible patients in need of this treatment option.


 Are there any ongoing collaborations or partnerships between Kite and healthcare providers, regulatory bodies, or other stakeholders in Singapore to enhance the adoption and accessibility of CAR T-cell therapy? If so, could you provide some examples or details?

Following the approval of axicabtagene ciloleucel by HSA in Singapore, Gilead and Kite Oncology are committed to qualify hospitals designated as authorised treatment centres and


to partner with the medical community to offer comprehensive training so that staff at certified healthcare facilities are equipped with the skills required to support patients.


How do you envision the role of government policies and regulations in facilitating the availability and affordability of CAR T-cell therapies? Are there any specific policy changes or initiatives that you believe would significantly impact access to these therapies in Singapore?

CAR T-cell therapy breaks new ground in cancer treatment and requires new processes and knowledge to support patient access.


Looking beyond Singapore, what are the opportunities and challenges in expanding access to CAR T-cell therapy across the Asia-Pacific region? Are there any regional trends or collaborations that could potentially influence the future landscape of CAR T- cell therapy in this region?

Gilead and Kite Oncology are committed to contributing towards making Singapore a center of excellence for CAR T-cell therapy in Southeast Asia, as Singapore is a leading biomedical sciences hub in Asia and has strategic geographical proximity to other countries in the region. Gilead and Kite Oncology in Singapore will be supported by our state-of-the-art manufacturing facilities.




1 Health Sciences Authority. (2023). Register of Class 2 cell, tissue or gene therapy products. [Online]. Available at: [Accessed date: June 2023




Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in